User login
Key clinical point: Pregnancy had no detrimental effects on survival outcomes and can be considered safe for young women who were previously diagnosed with and underwent treatment for hormone receptor-positive (HR+) early breast cancer (BC).
Major finding: Patients with a history of HR+ BC who did vs did not conceive after treatment showed better overall survival outcomes (hazard ratio 0.46; P < .005); however, the disease-free survival outcomes were comparable for both groups (P = .781).
Study details: Findings are from a meta-analysis of eight retrospective cohort studies including 3805 young women with HR+ invasive early BC, of whom 1285 women conceived post treatment.
Disclosures: This study was partially supported by the Italian Association for Cancer Research and the Italian Ministry of Health. Several authors declared receiving research support, honoraria, research funding, personal fees, grants, or consulting fees from or having ties with various sources.
Source: Arecco L et al. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: A systematic review and meta-analysis. ESMO Open. 2023;8(6):102031 (Oct 23). doi: 10.1016/j.esmoop.2023.102031
Key clinical point: Pregnancy had no detrimental effects on survival outcomes and can be considered safe for young women who were previously diagnosed with and underwent treatment for hormone receptor-positive (HR+) early breast cancer (BC).
Major finding: Patients with a history of HR+ BC who did vs did not conceive after treatment showed better overall survival outcomes (hazard ratio 0.46; P < .005); however, the disease-free survival outcomes were comparable for both groups (P = .781).
Study details: Findings are from a meta-analysis of eight retrospective cohort studies including 3805 young women with HR+ invasive early BC, of whom 1285 women conceived post treatment.
Disclosures: This study was partially supported by the Italian Association for Cancer Research and the Italian Ministry of Health. Several authors declared receiving research support, honoraria, research funding, personal fees, grants, or consulting fees from or having ties with various sources.
Source: Arecco L et al. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: A systematic review and meta-analysis. ESMO Open. 2023;8(6):102031 (Oct 23). doi: 10.1016/j.esmoop.2023.102031
Key clinical point: Pregnancy had no detrimental effects on survival outcomes and can be considered safe for young women who were previously diagnosed with and underwent treatment for hormone receptor-positive (HR+) early breast cancer (BC).
Major finding: Patients with a history of HR+ BC who did vs did not conceive after treatment showed better overall survival outcomes (hazard ratio 0.46; P < .005); however, the disease-free survival outcomes were comparable for both groups (P = .781).
Study details: Findings are from a meta-analysis of eight retrospective cohort studies including 3805 young women with HR+ invasive early BC, of whom 1285 women conceived post treatment.
Disclosures: This study was partially supported by the Italian Association for Cancer Research and the Italian Ministry of Health. Several authors declared receiving research support, honoraria, research funding, personal fees, grants, or consulting fees from or having ties with various sources.
Source: Arecco L et al. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: A systematic review and meta-analysis. ESMO Open. 2023;8(6):102031 (Oct 23). doi: 10.1016/j.esmoop.2023.102031